EasyChair Preprint

№ 13686

High-Flow Nasal Oxygen Therapy as an Adjunct Treatment in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Abill Robert

June 17, 2024

High-Flow Nasal Oxygen Therapy as an Adjunct Treatment in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Author

Abill Robert

Date: June 16, 2024

Abstract:

High-flow nasal oxygen (HFNO) therapy has emerged as a promising adjunct treatment in managing chronic obstructive pulmonary disease (COPD) exacerbations. COPD exacerbations, characterized by acute worsening of respiratory symptoms, often lead to significant morbidity, frequent hospitalizations, and increased healthcare costs. Traditional management strategies, including bronchodilators, corticosteroids, and antibiotics, have shown efficacy; however, the integration of HFNO therapy offers additional benefits. This therapy delivers heated, humidified oxygen at high flow rates, enhancing oxygenation and reducing the work of breathing.

Recent studies indicate that HFNO therapy can improve gas exchange, decrease respiratory rate, and enhance patient comfort compared to conventional oxygen therapy. Furthermore, HFNO therapy may reduce the need for invasive mechanical ventilation, thereby decreasing associated complications and mortality. This abstract aims to review the current evidence on HFNO therapy's efficacy, safety, and potential mechanisms of action in treating COPD exacerbations. By exploring the physiological benefits and clinical outcomes, this review seeks to establish HFNO therapy as a critical component in the comprehensive management of COPD exacerbations, highlighting its role in improving patient outcomes and optimizing respiratory care.

Introduction:

Chronic obstructive pulmonary disease (COPD) is a prevalent and progressive respiratory disorder characterized by persistent airflow limitation and chronic inflammatory response in the airways. It is a leading cause of morbidity and mortality worldwide, with exacerbations significantly impacting patient quality of life and healthcare systems. COPD exacerbations, defined as acute worsening of respiratory symptoms, often necessitate hospitalization and can lead to substantial declines in lung function. Managing these exacerbations effectively is crucial to reducing their frequency, severity, and associated healthcare costs.

Traditional treatments for COPD exacerbations typically include bronchodilators, corticosteroids, antibiotics, and supplemental oxygen. While these interventions have been

effective to some extent, there remains a significant need for additional therapeutic strategies that can enhance patient outcomes. High-flow nasal oxygen (HFNO) therapy has emerged as a promising adjunct treatment in this context.

HFNO therapy delivers heated, humidified oxygen at high flow rates, providing several physiological benefits over conventional oxygen therapy. It helps maintain mucociliary function, improves alveolar ventilation, and reduces the work of breathing. These attributes make HFNO particularly suitable for patients experiencing acute exacerbations of COPD, where optimizing oxygenation and reducing respiratory effort are critical goals.

II. Mechanisms and Benefits of HFNO in COPD Exacerbations

A. Physiological Effects

1. **Improved Oxygenation:** High-flow nasal oxygen (HFNO) therapy delivers oxygen at flow rates exceeding the patient's peak inspiratory flow, ensuring a constant supply of oxygen with minimal dilution by ambient air. This results in improved oxygenation compared to conventional low-flow oxygen therapies. The high flow of oxygen helps maintain a higher and more stable fraction of inspired oxygen (FiO2), effectively increasing arterial oxygen levels and reducing hypoxemia. This is particularly beneficial in COPD exacerbations, where impaired gas exchange and hypoxia are common challenges.
2. **Reduction in Work of Breathing:** HFNO therapy significantly reduces the work of breathing by providing a flow of oxygen that meets or exceeds the patient's spontaneous breathing demands. This reduces the need for the patient to generate high inspiratory efforts, thereby decreasing respiratory muscle fatigue. The positive airway pressure generated by high flow rates also helps to stent open the airways, reducing airway resistance and enhancing overall ventilation efficiency. This effect is crucial in COPD exacerbations, where patients often experience increased respiratory effort and breathlessness.
3. **Humidification and its Benefits:** The heated and humidified oxygen delivered by HFNO plays a vital role in maintaining mucociliary function and preventing airway desiccation. Proper humidification helps in keeping the respiratory mucosa moist, which enhances mucus clearance and reduces the risk of mucus plugging. Additionally, humidified air is more comfortable for patients to inhale, leading to better tolerance of the therapy and improved adherence. The benefits of humidification are particularly important in COPD patients, who are prone to thick mucus secretions and impaired mucociliary clearance.

B. Clinical Benefits

1. **Symptom Relief:** HFNO therapy has been shown to provide rapid symptom relief in patients experiencing COPD exacerbations. The combined effects of improved oxygenation, reduced work of breathing, and humidification contribute to a significant

decrease in symptoms such as breathlessness, fatigue, and overall respiratory distress. This immediate alleviation of symptoms can improve patient comfort and potentially reduce the need for more invasive interventions.

2. **Reduction in Respiratory Rate and Dyspnea:** Clinical studies have demonstrated that HFNO therapy can effectively lower the respiratory rate and reduce the sensation of dyspnea in patients with COPD exacerbations. By providing adequate oxygenation and reducing the effort required for breathing, HFNO therapy helps to normalize breathing patterns and decrease the frequency of labored breaths. This reduction in respiratory rate is an indicator of improved respiratory efficiency and a positive response to therapy.
3. **Enhanced Mucus Clearance:** The humidified air provided by HFNO aids in thinning mucus secretions, making them easier to expectorate. This enhanced mucus clearance is critical in COPD patients, who often suffer from chronic bronchitis and excessive mucus production. Improved mucus clearance reduces the risk of secondary infections and airway obstruction, contributing to better overall respiratory function and fewer exacerbations.

III. Evidence from Clinical Studies

A. Review of Randomized Controlled Trials (RCTs)

1. **Study Designs and Patient Populations:** Several RCTs have been conducted to evaluate the efficacy of high-flow nasal oxygen (HFNO) therapy in managing COPD exacerbations. These studies typically involve adult patients hospitalized with acute exacerbations of COPD. The study designs often include a comparison between HFNO therapy and conventional oxygen therapy or non-invasive ventilation (NIV). Patient populations are usually stratified based on severity of exacerbations, baseline oxygenation status, and comorbidities to ensure balanced and representative samples.
2. **Key Findings and Outcomes:** Key findings from RCTs indicate that HFNO therapy is associated with significant improvements in oxygenation, as measured by arterial blood gas (ABG) parameters and oxygen saturation levels. Studies have demonstrated a reduction in respiratory rate and dyspnea scores, highlighting the effectiveness of HFNO in relieving symptoms. Additionally, HFNO has been shown to reduce the need for intubation and mechanical ventilation compared to conventional oxygen therapy, thereby decreasing the incidence of associated complications. Overall, these trials suggest that HFNO therapy can lead to better clinical outcomes and enhanced patient comfort.

B. Observational Studies and Real-World Data

1. **Insights from Clinical Practice:** Observational studies and real-world data provide valuable insights into the practical application of HFNO therapy in diverse healthcare settings. These studies often involve larger and more heterogeneous patient populations than RCTs, offering a broader perspective on the therapy's effectiveness and safety. Clinical practice data indicate that HFNO is well-tolerated by patients and can be seamlessly integrated into existing treatment protocols for COPD exacerbations.

2. **Comparisons with Standard Oxygen Therapy:** Comparisons between HFNO and standard oxygen therapy in observational studies consistently show that HFNO provides superior oxygenation and respiratory support. Patients receiving HFNO often experience quicker symptom relief and a more stable clinical course. Additionally, real-world data suggest that HFNO can reduce the length of hospital stays and healthcare costs by decreasing the need for escalation to more intensive respiratory support modalities.

C. Meta-Analyses and Systematic Reviews

1. **Summary of Pooled Data:** Meta-analyses and systematic reviews consolidate findings from multiple studies, providing a comprehensive overview of the efficacy and safety of HFNO therapy in COPD exacerbations. Pooled data from these analyses confirm that HFNO significantly improves oxygenation and reduces respiratory distress compared to conventional oxygen therapy. The evidence also supports a lower risk of intubation and mechanical ventilation in patients treated with HFNO.
2. **Overall Efficacy and Safety:** The overall efficacy of HFNO therapy is supported by consistent improvements in key clinical outcomes, such as oxygen saturation, respiratory rate, and patient comfort. Systematic reviews emphasize the safety of HFNO, noting a low incidence of adverse effects and high patient tolerability. Furthermore, HFNO's ability to deliver humidified, heated oxygen reduces the risk of airway irritation and enhances mucus clearance, contributing to its favorable safety profile.

IV. Implementation and Practical Considerations

A. Patient Selection Criteria

1. **Identifying Suitable Candidates for HFNO:** Suitable candidates for high-flow nasal oxygen (HFNO) therapy include patients experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD) with moderate to severe hypoxemia who are not responding adequately to conventional oxygen therapy. These patients often present with increased work of breathing, elevated respiratory rates, and signs of respiratory distress. HFNO can also be considered for patients who are at risk of requiring intubation but may benefit from a less invasive form of respiratory support.
2. **Contraindications and Precautions:** Contraindications for HFNO therapy include patients with severe hypoxemia requiring immediate invasive mechanical ventilation, those with facial trauma or recent nasal surgery that may prevent the proper fitting of nasal cannulas, and patients with impaired consciousness or an inability to protect their airway. Precautions should be taken for patients with hypercapnia or those at risk of hypercapnic respiratory failure, as HFNO may not be sufficient to manage their condition without close monitoring. Regular assessment and monitoring are crucial to ensure the therapy's effectiveness and safety.

B. Protocols and Guidelines

1. **Initiation and Titration of HFNO:** HFNO therapy should be initiated at a flow rate of 20-30 liters per minute (L/min), gradually increasing to a maximum of 60 L/min based on patient tolerance and response. The fraction of inspired oxygen (FiO2) should be set to achieve a target oxygen saturation (SpO2) of 88-92%, adjusting as necessary. Initiation should begin with a lower flow rate to ensure patient comfort and then titrated upwards to optimize oxygenation and respiratory support.
2. **Monitoring and Managing Patient Response:** Continuous monitoring of SpO2, respiratory rate, heart rate, and overall clinical status is essential when administering HFNO. Arterial blood gas (ABG) measurements should be taken to assess oxygenation and ventilation status periodically. If the patient's condition does not improve or deteriorates, adjustments to flow rate, FiO2, or a switch to a different form of respiratory support may be necessary. Regular reassessment ensures that the therapy is effective and that any adverse effects are promptly addressed.

C. Integration into Existing COPD Management Plans

1. **Combining HFNO with Other Treatments:** HFNO therapy should be integrated with standard treatments for COPD exacerbations, including bronchodilators, corticosteroids, antibiotics (if indicated), and other supportive measures such as hydration and nutritional support. Coordination with the multidisciplinary team, including respiratory therapists, nurses, and physicians, is essential for comprehensive patient care.
2. **Adjustments Based on Patient Progress:** The use of HFNO should be dynamically adjusted based on the patient's progress and response to treatment. As the patient's respiratory status stabilizes and improves, the flow rate and FiO2 can be gradually weaned to transition back to conventional oxygen therapy or room air. Continuous evaluation of the patient's clinical status will guide the duration and intensity of HFNO therapy, ensuring that it is utilized effectively and safely.

V. Potential Challenges and Limitations

A. Technical and Logistical Issues

1. **Equipment Availability and Maintenance:** One of the primary challenges in implementing high-flow nasal oxygen (HFNO) therapy is ensuring the availability and maintenance of the necessary equipment. HFNO systems require specialized devices that can deliver heated, humidified oxygen at high flow rates. Hospitals and healthcare facilities need to invest in these systems and establish regular maintenance protocols to ensure their proper functioning. Equipment failures or shortages can impede the consistent delivery of HFNO therapy, potentially compromising patient care.
2. **Training Requirements for Healthcare Providers:** Effective utilization of HFNO therapy necessitates comprehensive training for healthcare providers, including respiratory therapists, nurses, and physicians. Training programs should cover the principles of HFNO therapy, proper device operation, patient selection criteria, and monitoring protocols. Additionally, providers need to be educated on troubleshooting

common issues and managing potential complications. Establishing and maintaining these training programs can be resource-intensive but is crucial for the safe and effective delivery of HFNO therapy.

B. Patient Adherence and Comfort

1. **Addressing Discomfort and Tolerance Issues:** Some patients may experience discomfort with HFNO therapy, particularly due to the high flow rates and nasal cannulas. Common complaints include nasal dryness, irritation, and a sensation of air hunger. Addressing these issues is essential to ensure patient adherence and therapeutic effectiveness. Solutions may include adjusting the flow rate, using humidified air to minimize dryness, and providing additional comfort measures such as nasal gels or frequent breaks from the therapy.
2. **Strategies to Enhance Patient Compliance:** Enhancing patient compliance involves clear communication about the benefits of HFNO therapy and addressing any concerns promptly. Educating patients about how the therapy works and what to expect can reduce anxiety and improve acceptance. Additionally, involving patients in their treatment plans and providing consistent support from healthcare providers can foster a positive attitude towards the therapy. Regular monitoring and feedback can also help to identify and resolve issues that may affect compliance.

C. Cost-Effectiveness

1. **Economic Considerations:** The implementation of HFNO therapy involves significant initial costs, including purchasing equipment and training healthcare providers. Ongoing expenses related to equipment maintenance, consumables, and operational costs must also be considered. Assessing the economic impact of HFNO therapy requires a thorough evaluation of these factors alongside the potential benefits in patient outcomes and reduced healthcare utilization.
2. **Comparative Cost Analysis with Other Treatments:** Conducting a comparative cost analysis with other treatments, such as conventional oxygen therapy and non-invasive ventilation (NIV), can provide insights into the cost-effectiveness of HFNO therapy. While HFNO may have higher upfront costs, its ability to reduce the need for intubation, shorten hospital stays, and improve patient outcomes could lead to overall cost savings. Studies have shown that HFNO can decrease the length of intensive care unit (ICU) stays and reduce the incidence of complications associated with invasive ventilation, potentially offsetting its initial costs.

VI. Future Directions and Research Opportunities

A. Innovations in HFNO Technology

1. **Advances in Device Design and Functionality:** Innovations in high-flow nasal oxygen (HFNO) technology are focused on enhancing device performance and patient comfort. Advances may include more compact and portable devices, improvements in noise reduction, and enhanced humidification systems. These developments aim to make HFNO therapy more user-friendly and accessible in various healthcare settings. Integration of smart technology, such as automated flow adjustments based on real-time patient monitoring, can further optimize the therapeutic benefits and minimize the need for manual adjustments by healthcare providers.
2. **Potential for Home-Based HFNO Therapy:** With the advent of more portable and user-friendly devices, there is significant potential for home-based HFNO therapy. This approach could allow for continuous respiratory support outside the hospital setting, particularly for patients with chronic respiratory conditions such as COPD. Home-based HFNO therapy can reduce hospital readmissions, improve quality of life, and provide a more comfortable environment for long-term treatment. However, it requires robust patient education, remote monitoring capabilities, and clear protocols to ensure safety and efficacy.

B. Ongoing and Future Clinical Trials

1. **Current Research Initiatives:** Several ongoing clinical trials are investigating various aspects of HFNO therapy in COPD exacerbations. These studies aim to further elucidate the benefits of HFNO in different patient populations, optimize treatment protocols, and compare HFNO with other respiratory support modalities. Current research focuses on determining the ideal flow rates and FiO2 settings, evaluating long-term outcomes, and identifying specific patient characteristics that predict positive responses to HFNO therapy.
2. **Areas Needing Further Investigation:** Despite promising findings, several areas require further research to maximize the potential of HFNO therapy. These include:
    - Long-term outcomes of HFNO therapy in COPD exacerbations.
    - The impact of HFNO on health-related quality of life.
    - Comparative effectiveness of HFNO versus non-invasive ventilation (NIV) in severe cases.
    - Identification of optimal weaning strategies from HFNO to conventional oxygen therapy.
    - Exploration of HFNO in other respiratory conditions and comorbidities commonly seen in COPD patients.

C. Personalized Medicine Approaches

1. **Tailoring HFNO Therapy to Individual Patient Profiles:** Personalized medicine approaches aim to customize HFNO therapy based on individual patient characteristics and needs. Factors such as the severity of COPD, comorbidities, baseline respiratory function, and patient preferences can guide the customization of HFNO settings and protocols. Personalizing HFNO therapy can enhance its efficacy, improve patient satisfaction, and reduce adverse effects.
2. **Role of Biomarkers and Predictive Modeling:** The integration of biomarkers and predictive modeling into HFNO therapy can facilitate more precise patient selection and treatment optimization. Biomarkers such as blood gases, inflammatory markers, and genetic profiles may help predict which patients are most likely to benefit from HFNO therapy. Predictive modeling, utilizing machine learning and artificial intelligence, can analyze large datasets to identify patterns and predictors of treatment success. These advancements can lead to more targeted and effective use of HFNO in managing COPD exacerbations.

VII. Conclusion

A. Summary of Key Points

High-flow nasal oxygen (HFNO) therapy has emerged as a valuable adjunct treatment for acute exacerbations of chronic obstructive pulmonary disease (COPD). The therapy offers several physiological benefits, including improved oxygenation, reduced work of breathing, and enhanced humidification, which collectively contribute to symptom relief, reduced respiratory rates, and better mucus clearance. Evidence from randomized controlled trials (RCTs), observational studies, and meta-analyses consistently supports the efficacy and safety of HFNO in improving clinical outcomes, such as lowering the need for invasive mechanical ventilation and reducing hospital stays.

B. Clinical Implications

The implementation of HFNO therapy in clinical practice has significant implications for patient outcomes and quality of life. By providing effective respiratory support that is less invasive than traditional mechanical ventilation, HFNO can enhance patient comfort, reduce the burden of dyspnea, and improve overall respiratory function during exacerbations. This therapy also offers potential healthcare cost savings by reducing ICU admissions and the length of hospital stays. The integration of HFNO into COPD management plans, alongside standard treatments, can lead to more comprehensive and effective care, ultimately enhancing patient quality of life.

C. Final Thoughts and Recommendations

HFNO therapy represents a promising advancement in the management of COPD exacerbations, offering a blend of clinical efficacy and patient-centered benefits. To optimize its use in clinical practice, healthcare providers should:

1. **Adopt Evidence-Based Protocols:** Implement standardized protocols for initiating, titrating, and monitoring HFNO therapy, ensuring consistency and safety across healthcare settings.
2. **Invest in Training and Education:** Provide comprehensive training for healthcare providers to ensure proper use of HFNO devices and management of patients receiving this therapy.
3. **Enhance Patient Compliance:** Address patient comfort and adherence issues through education, regular monitoring, and adjustments based on individual patient needs.
4. **Evaluate Cost-Effectiveness:** Conduct cost-benefit analyses to justify the investment in HFNO technology, considering long-term healthcare savings and improved patient outcomes.
5. **Promote Continued Research:** Support ongoing and future research to refine HFNO therapy protocols, explore its applications in other respiratory conditions, and develop personalized treatment approaches using biomarkers and predictive modeling.

REFERENCE

1. Azoulay, E., Lemiale, V., Mokart, D., Nseir, S., Argaud, L., Pène, F., Kontar, L., Bruneel, F., Klouche,K., Barbier, F., Reignier, J., Berrahil-Meksen, L., Louis, G., Constantin, J. M., Mayaux, J., Wallet, F., Kouatchet, A., Peigne, V., Théodose, I., . . . Demoule, A. (2018). Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure. *JAMA*, *320*(20), 2099. https://doi.org/10.1001/jama.2018.14282

2. Moustafa, A. H., & Shallik, N. A. (2019). Radiological evaluation of the airway: One-stop shop. *Virtual Endoscopy and 3D Reconstruction in the Airways*, 15-29.

3. Frat, J. P., Coudroy, R., Marjanovic, N., & Thille, A. W. (2017a). High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. *Annals of Translational Medicine*, *5*(14), 297. https://doi.org/10.21037/atm.2017.06.52

4. Shallik, N. A. B. I. L. (2015). Anesthetic management for drug induced sleep endoscopy. *Middle East J Anaesthesiol*, *23*(2), 131-135.

5. Shallik, N., Hammad, Y., Sadek, M., & Feki, A. (2018). Effect of endotracheal tube size and cuff pressure on incidence of postoperative sore throat: Comparison between three facilities. *Trends in Anaesthesia and Critical Care*, *23*, 16-17.

6. Roehrig, S., Ait Hssain, A., Shallik, N. A. H., Elsaid, I. M. A., Mustafa, S. F., Smain, O. A., ... & Lance, M. D. (2020). Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial. *Trials*, *21*, 1-2.

7. Groves, N., & Tobin, A. (2007). High flow nasal oxygen generates positive airway pressure in adult volunteers. *Australian Critical Care*, *20*(4), 126–131. https://doi.org/10.1016/j.aucc.2007.08.001

8. Shallik, N., et al. "The use of virtual endoscopy for diagnosis of traumatic supra-glottic airway stenosis." *JCAO* 2.1 (2017): 103

9. Lenglet, H., Sztrymf, B., Leroy, C., Brun, P., Dreyfuss, D., & Ricard, J. D. (2012). Humidified High Flow Nasal Oxygen During Respiratory Failure in the Emergency Department: Feasibility and Efficacy. *Respiratory Care*, *57*(11), 1873–1878. https://doi.org/10.4187/respcare.01575

10. Lyons, C., & Callaghan, M. (2017). Apnoeic oxygenation with high-flow nasal oxygen for laryngeal surgery: a case series. *Anaesthesia*, *72*(11), 1379–1387. https://doi.org/10.1111/anae.14036

11. Renda, T., Corrado, A., Iskandar, G., Pelaia, G., Abdalla, K., & Navalesi, P. (2018). High-flow nasal oxygen therapy in intensive care and anaesthesia. *British Journal of Anaesthesia*, *120*(1), 18–27. https://doi.org/10.1016/j.bja.2017.11.010

12. Satoh, S., Watanabe, J., Keitoku, M., Itoh, N., Maruyama, Y., & Takishima, T. (1988). Influences of pressure surrounding the heart and intracardiac pressure on the diastolic coronary pressure-flow relation in excised canine heart. *Circulation Research*, *63*(4), 788–797. https://doi.org/10.1161/01.res.63.4.788

13. Spoletini, G., Alotaibi, M., Blasi, F., & Hill, N. S. (2015). Heated Humidified High-Flow Nasal Oxygen in Adults. *Chest*, *148*(1), 253–261. https://doi.org/10.1378/chest.14-2871

14. Stéphan, F., Barrucand, B., Petit, P., Rézaiguia-Delclaux, S., Médard, A., Delannoy, B., Cosserant, B., Flicoteaux, G., Imbert, A., Pilorge, C., & Bérard, L. (2015). High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery. *JAMA*, *313*(23), 2331. https://doi.org/10.1001/jama.2015.5213